H Kiyama1, N Ohshima, T Imazeki. 1. Department of Cardiovascular and Thoracic Surgery, Dokkyo University Koshigaya Hospital, Saitama, Japan.
Abstract
OBJECTIVE: To determine the safety and effectiveness of blood donation in anemic patients, we harvested blood from cardiac patients with baseline hemoglobin levels below 11.0 g/dl. METHODS:Subjects were 118 patients who underwent elective cardiac surgery between January 1994 and October 1997. We assigned patients to 1 of 2 groups based on their entry hemoglobin level: an anemic group (hemoglobin < 11.0 g/dl, n = 20) and a nonanemic group (hemoglobin > or = 11.0 g/dl, n = 98). All patients received subcutaneous administration of recombinant human erythropoietin, and autologous blood was collected once a week for at least 3 weeks before the scheduled surgery date if the hemoglobin level exceeded 10.5 g/dl. RESULTS: No statistically significant differences were seen between the 2 groups in patient profiles or surgical data. The estimated hemoglobin increase did not differ significantly between groups at any time point. The total collected blood volume per patient was greater in the nonanemic group than in the anemic group (1098 +/- 224 ml vs. 712 +/- 334 ml), but the difference in volume was not statistically significant. The percentage of patients who received allogeneic blood did not differ significantly between groups. No side effects were associated with hemoglobin level prior to donation because the incidence of side effects was similar across hemoglobin levels. CONCLUSIONS: This study suggests that autologous blood donation reduces the need for allogeneic blood in patients with baseline hemoglobin levels below 11.0 g/dl.
RCT Entities:
OBJECTIVE: To determine the safety and effectiveness of blood donation in anemicpatients, we harvested blood from cardiac patients with baseline hemoglobin levels below 11.0 g/dl. METHODS: Subjects were 118 patients who underwent elective cardiac surgery between January 1994 and October 1997. We assigned patients to 1 of 2 groups based on their entry hemoglobin level: an anemic group (hemoglobin < 11.0 g/dl, n = 20) and a nonanemic group (hemoglobin > or = 11.0 g/dl, n = 98). All patients received subcutaneous administration of recombinant humanerythropoietin, and autologous blood was collected once a week for at least 3 weeks before the scheduled surgery date if the hemoglobin level exceeded 10.5 g/dl. RESULTS: No statistically significant differences were seen between the 2 groups in patient profiles or surgical data. The estimated hemoglobin increase did not differ significantly between groups at any time point. The total collected blood volume per patient was greater in the nonanemic group than in the anemic group (1098 +/- 224 ml vs. 712 +/- 334 ml), but the difference in volume was not statistically significant. The percentage of patients who received allogeneic blood did not differ significantly between groups. No side effects were associated with hemoglobin level prior to donation because the incidence of side effects was similar across hemoglobin levels. CONCLUSIONS: This study suggests that autologous blood donation reduces the need for allogeneic blood in patients with baseline hemoglobin levels below 11.0 g/dl.
Authors: L T Goodnough; S Rudnick; T H Price; S K Ballas; M L Collins; J P Crowley; M Kosmin; M S Kruskall; B A Lenes; J E Menitove Journal: N Engl J Med Date: 1989-10-26 Impact factor: 91.245
Authors: W J Scott; R Rode; B Castlemain; R Kessler; F Follis; S B Pett; J A Wernly Journal: J Thorac Cardiovasc Surg Date: 1992-05 Impact factor: 5.209
Authors: D M Cosgrove; F D Loop; B W Lytle; C C Gill; L R Golding; P C Taylor; S B Forsythe Journal: Ann Thorac Surg Date: 1985-10 Impact factor: 4.330
Authors: Y Watanabe; K Fuse; Y Naruse; T Kobayashi; S Yamamoto; H Konishi; T Horii; Y Shibata Journal: Ann Thorac Surg Date: 1992-09 Impact factor: 4.330